Interface Laboratories

🔬 C. difficile Diagnostics VALIDATION

We are developing breakthrough diagnostic approaches that can rapidly and accurately distinguish between C. difficile colonization and active infection - solving one of the most significant challenges in clinical microbiology. Our preliminary data demonstrates improved specificity compared to current molecular methods, which often lead to false positive results when patients are merely colonized rather than infected.

This represents a critical advancement in clinical diagnostics, as current methods cannot reliably differentiate harmless colonization from disease-causing infection. The inability to make this distinction results in massive overtreatment, unnecessary antibiotic exposure, increased healthcare costs, and accelerated antimicrobial resistance development.

💊 Antimicrobial Drug Discovery PRECLINICAL

Using structure-based drug design and computational modeling, we are identifying novel compounds active against resistant fungal and parasitic pathogens. Our lead compounds show promising activity in preliminary in vitro studies. We focus on neglected tropical diseases and infections that disproportionately affect immunocompromised patients, where current treatment options are limited or toxic.

🧬 Metagenomic Analysis Tools BETA

Our BioGPU platform applies machine learning and advanced algorithms to metagenomic data, enabling rapid identification of pathogens and resistance markers from complex microbial communities. This tool can process sequencing data in hours rather than days, providing clinicians with actionable information for treatment decisions. Current beta testing is demonstrating significant improvements in speed and accuracy compared to traditional bioinformatics pipelines.

📊 Therapeutic Drug Monitoring ACTIVE

We are establishing correlations between antimicrobial concentrations in different body compartments (blood, stool, tissue) and clinical outcomes. Our goal is to develop personalized dosing strategies that maximize efficacy while minimizing toxicity and resistance development. This precision medicine approach is particularly important for drugs with narrow therapeutic windows or high inter-patient variability.